Arvinas (NASDAQ:ARVN) Announces Earnings Results, Beats Estimates By $0.05 EPS

Arvinas (NASDAQ:ARVN) released its earnings results on Tuesday. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.05, FiscalAI reports. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The firm had revenue of $15.60 million during the quarter, compared to analysts’ expectations of $16.61 million. During the same period in the previous year, the firm posted $1.14 EPS. Arvinas’s revenue for the quarter was down 91.7% on a year-over-year basis.

Here are the key takeaways from Arvinas’ conference call:

• Arvinas announced FDA approval of VEPPANU and a global licensing agreement with Rigel Pharmaceuticals, which will handle commercialization, development, and manufacturing. Management said the deal lets Arvinas focus capital on its next wave of pipeline programs while still benefiting economically through the partnership.
• The company’s ARV-102 PSP trial in the U.S. is on clinical hold after the FDA requested final chronic tox data from non-human primates before allowing initiation. Arvinas now expects those data in mid-2026 and the U.S. trial to begin by the end of 2026.
• Phase I data for ARV-102 in Parkinson’s disease showed about 50% or greater CSF LRRK2 reductions, downstream biomarker improvements, and good tolerability with no serious adverse events through 28 days. Management said these results support moving the program into PSP, where they see a strong mechanistic and biomarker rationale.
• ARV-806, the KRAS G12D degrader, completed dose-escalation enrollment ahead of schedule, and the company expects initial clinical data later this year. Arvinas believes the asset’s potency and durability could support differentiation in a crowded KRAS landscape.
• The company continues to advance a broad pipeline, including ARV-393 in lymphoma, ARV-027 in SBMA, and ARV-6723 (HPK1) heading toward the clinic later this year. Arvinas also highlighted improved cash visibility, saying its balance sheet and cost reductions support operations into the second half of 2028.

Arvinas Price Performance

Shares of ARVN traded down $0.26 during mid-day trading on Thursday, reaching $9.62. 59,756 shares of the company’s stock were exchanged, compared to its average volume of 846,764. The business’s fifty day simple moving average is $11.14 and its 200-day simple moving average is $11.69. The stock has a market capitalization of $620.36 million, a PE ratio of -2.87 and a beta of 1.79. Arvinas has a 52-week low of $5.90 and a 52-week high of $14.51.

Insider Activity

In other news, Director John G. Houston sold 35,297 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $13.21, for a total transaction of $466,273.37. Following the completion of the sale, the director owned 1,122,183 shares in the company, valued at approximately $14,824,037.43. This represents a 3.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew Saik sold 11,139 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the transaction, the chief financial officer owned 193,128 shares in the company, valued at $1,919,692.32. This trade represents a 5.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 97,687 shares of company stock worth $1,138,643 over the last 90 days. 7.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ARVN. Intech Investment Management LLC lifted its holdings in shares of Arvinas by 3.6% during the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock worth $278,000 after purchasing an additional 1,125 shares during the period. MetLife Investment Management LLC boosted its holdings in shares of Arvinas by 4.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock valued at $401,000 after acquiring an additional 1,381 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Arvinas by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after acquiring an additional 2,122 shares during the period. Oxford Asset Management LLP increased its stake in shares of Arvinas by 15.5% during the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after acquiring an additional 2,242 shares during the period. Finally, Entropy Technologies LP raised its holdings in Arvinas by 8.6% during the third quarter. Entropy Technologies LP now owns 35,295 shares of the company’s stock worth $301,000 after purchasing an additional 2,804 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Key Headlines Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and kept a Buy rating, reflecting improved Wall Street confidence in upside from current levels. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer licensed their breast cancer drug VEPPANU (vepdegestrant) to Rigel Pharmaceuticals in a deal that includes $85 million upfront and up to $320 million in milestones, which validates the company’s PROTAC platform and could bring in meaningful non-dilutive funding. Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
• Neutral Sentiment: Arvinas’ Q1 results showed a smaller-than-expected loss of $0.90 per share, but revenue of $15.6 million missed estimates and fell sharply year over year, underscoring that profitability is still not near-term. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: CEO Randy Teel, CFO Andrew Saik, CAO David Loomis, and insider Noah Berkowitz all sold shares recently, which can weigh on sentiment even though the filings say the sales were primarily to cover tax withholding from equity vesting. CEO insider filing

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a research report on Friday, April 10th. Barclays raised their price objective on shares of Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday. Truist Financial set a $10.00 target price on shares of Arvinas in a report on Wednesday, March 18th. Citigroup lifted their price target on shares of Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Finally, Wedbush boosted their price target on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Arvinas currently has an average rating of “Hold” and a consensus price target of $15.14.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.